15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function.

          Related collections

          Author and article information

          Journal
          Gastroenterology
          Gastroenterology
          Elsevier BV
          1528-0012
          0016-5085
          Jul 2011
          : 141
          : 1
          Affiliations
          [1 ] Larry L. Hillblom Islet Research Center at David Geffen School of Medicine and Department of Biomathematics, University of California, Los Angeles, California 90095-7073, USA.
          Article
          S0016-5085(11)00172-7 NIHMS675954
          10.1053/j.gastro.2011.02.018
          4404515
          21334333
          bbe3b7ba-14c8-4f38-88bc-8da6f6873ef8
          Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article